M.D. Anderson Cancer Center
This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell transplant. Chemotherapy drugs, such as venetoclax, busulfan, cladribine, and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax to the current standard of care stem cell transplant regimen of busulfan, fludarabine, and cladribine may help to control high-risk acute myeloid leukemia or myelodysplastic syndrome.
Phase 2 Portion Primary Objective 1) To obtain preliminary evidence of efficacy as defined by 1-year progression free survival. Secondary Objectives To determine: 1. Safety of this regimen as per NCI toxicity criteria 2. Time to neutrophil and platelet engraftment 3. Incidence of acute and chronic GVHD 4. Relapse incidence 5. Non-relapse mortality 6. Overall survival 7. Graft versus host disease-relapse free survival (GRFS) Phase 3 Portion Primary Objective 1\) To compare progression free survival between two arms Arm 1 Standard of Care: fludarabine + IV busulfan (FluBu) versus Arm 2 Ex…
Inclusion Criteria: Phase II 1. Age ≥ 18 and ≤ 70 years. English and non-English speaking patients are eligible. 2. Patients with acute myeloid leukemia who have previously received induction therapy and one of the following high-risk features: 1. ELN17 adverse risk prognostic group irrespective of remission status (see Appendix 2) 2. Measurable residual disease positive (MRD +) 3. Not in complete remission including complete remission without count recovery (Cri) and/or morphologic leukemia free state (MLFS), primary refractory, or relapsed disease. See Appendix 3 for details.…
Given IV
Given IV
Given IV
Undergo stem cell transplantation
Given IV
Given PO
Arctuva estimate
Verify or correct the compensation shown for this listing.